Summary
Celgene announces positive preliminary data from its study treating patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) using JCAR017.
A key risk is whether or not hospitals and insurers will pay the hefty price tag of CAR-T therapies, which may impact sales.
Of the 81% of patients that got an ORR who were treated with JCAR017, 43% achieved a complete response.
It is estimated that the global CAR-T cell therapy market could be worth $8 billion by 2028.
Competition is strong in the lymphoma space using CAR-T. Such companies are, for instance, Novartis with Kymriah and Gilead Sciences with Yescarta.
Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our model portfolio. Start your free trial today »
Recently, Celgene (CELG) announced preliminary data from its study treating patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data shown was from the dose escalation part of an ongoing, open-label multicenter phase 1/2 study using JCAR017 to treat these patients. I think that the preliminary data is strong, especially when you consider that a large chunk of this population were given prior treatment with ibrutinib and had cytogenetic features of high-risk disease. This data is preliminary, but it is quite strong.
